Monoclonal antibodies offer key opportunities in precision immunotherapy for cancer and chronic diseases. Focus areas include targeted novel therapies, stereo-specific antibodies for enhanced efficacy ...

Vascular Endothelial Growth Factor Inhibitor market grows 4.0% CAGR as biosimilars and personalized medicine expand ...

Eli Lilly and Company (NYSE:LLY) is included among the 16 Best Dividend Stocks with Rising Payouts. According to a Reuters ...

The Australian company will retain rights for an end-stage kidney disease indication currently being tested in a Phase 3 trial while Lilly explores other uses.

Immunoprecipitation-enhanced blood-based biomarkers are improving early diagnosis of Alzheimer’s disease by enabling more ...

Coherus BioSciences shows underwhelming LOQTORZI sales and reliance on upcoming pipeline catalysts. Read why CHRS stock is ...

Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI responseDurable Clinical Observations ...

Zenyaku Kogyo obtains Japanese approval for anti-CD20 monoclonal antibody, Rituxan to treat autoimmune haemolytic anaemia: Tokyo Friday, February 20, 2026, 13:00 Hrs [IST] Zenyaku ...

Australia's CSL said on Wednesday it has granted Eli Lilly certain rights to develop and commercialize clazakizumab, an ...

Over 95% of the world's adult population is infected with Epstein-Barr virus (EBV), but most people never realize it. The infection often causes few symptoms and then stays in the body for life.

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to ...

Adults with primary membranous nephropathy achieved higher complete remission rates with obinutuzumab than tacrolimus in the pivotal phase 3 MAJESTY trial.